Clinical trial
An Open Label, Single Arm, Phase II Study of Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients, in Order to Verify Disappearance of CD34+/Lin-Ph+ Cells From Bone Marrow During Treatment
NCT01856283 is registered in ClinicalTrials.gov with Niguarda Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open Label, Single Arm, Phase II Study of Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients, in Order to Verify Disappearance of CD34+/Lin-Ph+ Cells From Bone Marrow During Treatment
- Lead sponsor
- Niguarda Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2013
- Completion date
- January 31, 2021
- Enrollment
- 87 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.